drugset / Trial / NCT00998192

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

NCT00998192

Phase 2 Completed 32 enrolled Oncolytics Biotech University of Texas · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with paclitaxel and carboplatin is effective and safe in the treatment of squamous cell carinoma of the lung.

Timeline

Start
2009-10
Primary completion
2013-09
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Pelareorep Other / unclassified 3e+10 unknown Intravenous
Background Carboplatin Small molecule 6 unknown Intravenous
Background Paclitaxel Small molecule 200 mg/m2 Intravenous